These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 8146831)

  • 1. [Allergy to drug-coloring agents. Comparison of reported cases and the experience of the Regional Center of Pharmacovigilance].
    Vandelle C; Belegaud D; Bidault I; Castot A
    Therapie; 1993; 48(5):484-5. PubMed ID: 8146831
    [No Abstract]   [Full Text] [Related]  

  • 2. [Official systems of pharmacovigilance in France and in Spain. Comparison of spontaneous reporting in two regional centers: Pays Basque and Bordeaux].
    Aguirre C; Haramburu F
    Therapie; 1995; 50(6):563-9. PubMed ID: 8745957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Users of a regional center of pharmacovigilance].
    Haramburu F; Abraham E; Bégaud B
    Therapie; 1993; 48(5):475-7. PubMed ID: 8146828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Joint program of pharmacovigilance in Quebec: comparison with France, Aquitaine and the Basque region].
    Biron P; Balency D
    Therapie; 1996; 51(5):578-81. PubMed ID: 9138400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Good practices of publication of clinical cases of pharmacovigilance: comments, Groupe de Travail sur les Bonnes Pratiques de Publication de Cliniques en Pharmacovigilance: commentary].
    Auriche M; Bertrand P; Blay N; Danan G; Hamel JD; Imbs JL; Lagier G; Micaleff A; Moore N; Ollagnier M; Reveilleau-Richard S; Soubrié C; Weber F
    Therapie; 1997; 52(2):123-7. PubMed ID: 9231506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Good practices in pharmacovigilance. Drugs for human use].
    Therapie; 1995; 50(6):547-55. PubMed ID: 8745955
    [No Abstract]   [Full Text] [Related]  

  • 7. [Pharmacovigilance off the beaten track: herbal surveillance or pharmacovigilance of medicinal plants].
    Castot A; Djezzar S; Deleau N; Guillot B; Efthymiou ML
    Therapie; 1997; 52(2):97-103. PubMed ID: 9231502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Highlights of the 22nd French pharmacovigilance meeting.
    Prescrire Int; 2002 Feb; 11(57):21-3. PubMed ID: 11985373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacovigilance of drug allergy and hypersensitivity using the ENDA-DAHD database and the GALEN platform. The Galenda project.
    Bousquet PJ; Demoly P; Romano A; Aberer W; Bircher A; Blanca M; Brockow K; Pichler W; Torres MJ; Terreehorst I; Arnoux B; Atanaskovic-Markovic M; Barbaud A; Bijl A; Bonadonna P; Burney PG; Caimmi S; Canonica GW; Cernadas J; Dahlen B; Daures JP; Fernandez J; Gomes E; Gueant JL; Kowalski ML; Kvedariene V; Mertes PM; Martins P; Nizankowska-Mogilnicka E; Papadopoulos N; Ponvert C; Pirmohamed M; Ring J; Salapatas M; Sanz ML; Szczeklik A; Van Ganse E; De Weck AL; Zuberbier T; Merk HF; Sachs B; Sidoroff A;
    Allergy; 2009 Feb; 64(2):194-203. PubMed ID: 19178398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A one-year evaluation of collaboration between an hospital allergy unit and a regional center of pharmacovigilance].
    Perault MC; Breuil K; DeJean C; Rivet G; Vandel B
    Therapie; 1990; 45(5):435. PubMed ID: 2260039
    [No Abstract]   [Full Text] [Related]  

  • 11. Adverse drug reactions and reporting.
    Witte R
    Clin J Oncol Nurs; 2000; 4(4):181, 184. PubMed ID: 11261100
    [No Abstract]   [Full Text] [Related]  

  • 12. [A 30-month study of the calls to the Regional Drug Monitoring Center in Lorraine (Nancy)].
    Trechot PF; Royer RJ; Gaire M; Gaspard MC; Netter P
    Therapie; 1990; 45(1):43-6. PubMed ID: 2343435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacovigilance of self-medication].
    Montastruc JL; Bagheri H; Geraud T; Lapeyre-Mestre M
    Therapie; 1997; 52(2):105-10. PubMed ID: 9231503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Vaccines' adverse events: questions and answers brought by InfoVac].
    Cohen R; Siegrist CA
    Arch Pediatr; 2006 Jun; 13(6):650-2. PubMed ID: 16690277
    [No Abstract]   [Full Text] [Related]  

  • 15. Assessment of utilization and pharmacovigilance based on spontaneous adverse event reporting of gadopentetate dimeglumine as a magnetic resonance contrast agent after 45 million administrations and 15 years of clinical use.
    Knopp MV; Balzer T; Esser M; Kashanian FK; Paul P; Niendorf HP
    Invest Radiol; 2006 Jun; 41(6):491-9. PubMed ID: 16763467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. European pharmacovigilance: an overview of pharmacovigilance inspections.
    Koster MC; van den Oetelaar AH
    Pharmacoepidemiol Drug Saf; 2005 Oct; 14(10):711-3. PubMed ID: 16142691
    [No Abstract]   [Full Text] [Related]  

  • 17. European pharmacovigilance legislation: has it led to implementation of pharmacovigilance inspections?
    Bleumink GS; in't Veld BA; Stricker BH
    Pharmacoepidemiol Drug Saf; 2001; 10(4):339-40. PubMed ID: 11760496
    [No Abstract]   [Full Text] [Related]  

  • 18. [Post licensure safety surveillance for Prevenar].
    Bensouda-Grimaldi L; Jonville-Béra AP; Autret-Leca E
    Arch Pediatr; 2007 Jul; 14(7):870-4. PubMed ID: 17442548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postmarketing hepatic adverse event experience with PEGylated/non-PEGylated drugs: a disproportionality analysis.
    Hauben M; Vegni F; Reich L; Younus M
    Eur J Gastroenterol Hepatol; 2007 Nov; 19(11):934-41. PubMed ID: 18049161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacovigilance of vaccines].
    Autret-Leca E; Bensouda-Grimaldi L; Jonville-Béra AP; Beau-Salinas F
    Arch Pediatr; 2006 Feb; 13(2):175-80. PubMed ID: 16343870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.